Work Here?
The Michael J. Fox Foundation
Work Here?
Funds and accelerates Parkinson's disease research
The Michael J. Fox Foundation
Work Here?
Funds and accelerates Parkinson's disease research
Overview
What does the Michael J. Fox Foundation do? It funds Parkinson's disease research with a focus on speed and scale, to move science toward a cure and better treatments. How does its work operate? It provides grants and resources to scientists, supports collaborations, and helps advance therapies from discovery to clinical testing, so new drugs and treatments reach patients sooner. How is it different from others? It concentrates only on Parkinson's research, targets aggressive funding and practical translation of findings into therapies, and works across the research community to accelerate progress. What is its goal? To find a cure for Parkinson's disease and to ensure improved therapies are available for people living with it today.
About The Michael J. Fox Foundation
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
New York City, New York
Founded
2000
People at The Michael J. Fox Foundation
People at The Michael J. Fox Foundation who can refer or advise you
Simplify's Take
What believers are saying
- MJFF grants $3.4M to Lysoway and $2.5M to Neuron23, accelerating lysosomal and LRRK2 drug trials
- MJFF partners Biognosys to de-risk LRRK2 trials via quantitative proteomics biomarker qualification
- Altura expands MJFF access to PPMI/BLAAC PD via 350k providers, boosting underrepresented community enrollment
What critics are saying
- Denali's DNL151 failed Phase 3 LIGHTHOUSE in 2023 due to timeline delays, risking LITE partner attrition within 6–12 months
- Neuron23's NEU-411 targets only 2% LRRK2-mutated cohort, risking underenrollment despite genetic testing expansion to 30% idiopathic cases in 12–18 months
- Lysoway's TMEM175 agonist faces existential risk: mutations increase PD risk but lack causal mechanism, risking failure in 24–36 months
What makes The Michael J. Fox Foundation unique
- MJFF uniquely funds LRRK2 biomarker assays and lysosomal targets like TMEM175 and PLA2G15 simultaneously
- MJFF integrates LITE program with global consortia PPMI and BLAAC PD for diverse patient recruitment
- MJFF pioneers rapid LRRK2 activation assays using S1292 autophosphorylation as a novel PD progression biomarker
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Flexible Spending Accounts
Life Insurance
Disability Insurance
Paid Vacation
Paid Sick Leave
Hybrid Work Options
Flexible Work Hours
Company News
London, 31 March 2025 – Endlyz Therapeutics officially emerges from stealth, unveiling its therapeutic pipeline of small molecule modulators targeting ATP13A2 and ATP10B to restore lysosomal function in Parkinson’s (PD) and other neurodegenerative diseases. The company also announces:
The Michael J. Fox Foundation is Hiring for 12 Jobs on Simplify!
Find jobs on Simplify and start your career today
About The Michael J. Fox Foundation
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
New York City, New York
Founded
2000
The Michael J. Fox Foundation is Hiring for 12 Jobs on Simplify!
Find jobs on Simplify and start your career today